VAERS Explorer
Back to explore

Report #2884400

Received Feb 5, 2026

A note on interpretation. VAERS reports are unverified and may be incomplete or coincidental. A report does not establish that a vaccine caused an event, and counts should not be used to calculate incidence or infer causation. Full disclaimer

Overview

Sex
Unknown
Age
Age unknown
State
TX
Recovered
Unknown
Vaccinated
Feb 4, 2026
Onset
Feb 4, 2026
Days to onset
0
Hospital days
—

Vaccines (1)

TypeNameManufacturerDoseLotRoute / Site
HPV9HPV (GARDASIL 9)MERCK & CO. INC.UNKY013768—

Symptoms (2)

Product administered to patient of inappropriate ageWrong product administered

Symptom narrative

HCP did not report any side effects due to the inadvertent administration of the GARDASIL 9 vaccine; HCP reported that a 6 month old male patient was inadvertently administered the GARDASIL 9 vaccine instead of the "PREVNAR vaccine".; HCP reported that a 6 month old male patient was inadvertently administered the GARDASIL 9 vaccine instead of the "PREVNAR vaccine".; This spontaneous report was received from a medical assistant and refers to a 6-month-old patient of unknown gender. The patient's medical history, concurrent conditions and concomitant therapies were not reported. On 04-Feb-2026, the patient was vaccinated with a dose of Human Papillomavirus 9-valent Vaccine, Recombinant (GARDASIL 9) (lot #Y013768 with valid expiration date reported as 12-Feb-2027) (dose, route of administration and vaccination site were not reported) administered for prophylaxis (product administered to patient of inappropriate age). The 6 month old male patient was inadvertently administered the Human Papillomavirus 9-valent Vaccine, Recombinant (GARDASIL 9) vaccine instead of the Pneumococcal vaccine conj 7v (CRM197) (PREVNAR) vaccine (wrong product administered). The medical assistant did not elaborate which Prevnar vaccine was intended to be administered to the patient. No side effects due to the inadvertent administration of the Human Papillomavirus 9-valent Vaccine, Recombinant (GARDASIL 9) vaccine was reported. No additional adverse event (AE) and no product quality complaint (PQC) was reported (no adverse event)